#	Pagina
attuale pagina	/open-h2020/projects/216999/index.html
-1	/open-h2020/projects/209392/results.html
-2	/open-h2020/projects/213086/deliverables.html
-3	/open-h2020/per-topic/cautiously/list/index.html
-4	/open-h2020/projects/206807/results.html
-5	/open-h2020/per-topic/intraplate/list/index.html
-6	/open-h2020/per-topic/gabaergic/list/index.html
-7	/open-h2020/projects/197494/results.html
-8	/open-h2020/per-topic/tomres/list/index.html
-9	/open-h2020/projects/212883/index.html
-10	/open-h2020/projects/205589/deliverables.html

Opendata, web and dolomites

TLA-Gut SIGNED

Novel Personalized Cellular Therapy Approach for Immune Diseases

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

TLA-Gut project word cloud

Explore the words cloud of the TLA-Gut project. It provides you a very rough idea of what is the project "TLA-Gut" about.

6 group cells life efficient personalized gap treatment business inflammatory blood karolinska immune diseases medical direct triggered tla create sweden carry causing date leukapheresis treatments commercialise efficacy clinical internationally demand disease threatening treat close proven billion therapeutic praxis aligned burden caused device enabler stockholm tissues market ibd performed maintained socio economic completion therapies once poses exists rate satiate removing 60 option induce opportunity positioned inflammation therapy first bowel trial remaining safe vivo remission imbalance belongs commercialisation cytokines risk mediated chemotaxis exaggerated institutet proof shown healthcare strategy imids release site patients migrate gut globally regulatory patient clinicians

Project "TLA-Gut" data sheet

The following table provides information about the project.

Coordinator	TLA TARGETED IMMUNOTHERAPIES AB Organization address address: EKONOMILANKEN AB BOX 726 city: SOLLENTUNA postcode: 191 27 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	http://www.tlatherapies.com/
Total cost	3˙850˙000 €
EC max contribution	2˙695˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-07-01 to 2021-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	TLA TARGETED IMMUNOTHERAPIES AB TLA TARGETED IMMUNOTHERAPIES AB Organization address address: EKONOMILANKEN AB BOX 726 city: SOLLENTUNA postcode: 191 27 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (SOLLENTUNA)	coordinator	2˙695˙000.00

Map

Project objective

This project will commercialise TLA Gut - the novel medical device for the treatment of Inflammatory Bowel Disease (IBD). IBD belongs to the group of Immune Mediated Inflammatory Diseases (IMIDs) caused and maintained by an exaggerated inflammatory response triggered by an imbalance of the immune system. Research at Karolinska Institutet in Sweden has shown that IMIDs are caused by increase in specific inflammatory cells, which migrate to the site of inflammation by chemotaxis and induce disease-causing inflammation through release of cytokines in tissues. TLA Gut is a globally unique technology, and the first medical device with a proven clinical efficacy in removing those disease-causing cells from the blood of the patient through therapeutic leukapheresis. Today, the development and commercialisation of new therapies for IBD is in great demand among clinicians and their patients as current treatments offer an overall long-term remission rate of only 50-60% and carry the risk of life-threatening side effects. There exists a strong business opportunity for a therapy that would create a new and personalized way to treat IBD. TLA Gut is positioned to satiate this demand. To date, TLA Gut in vivo proof of concept has been established in a Phase I/II clinical trial on IBD patients in Stockholm. In the project, the Phase III study will be performed together with regulatory development work required to get market access upon completion of the project. IBD poses a significant socio-economic burden internationally. In Europe, a direct healthcare cost of IBD is estimated to € 4.6–5.6 billion per year. Once introduced in the clinical praxis across the EU, TLA Gut will be a safe and cost-efficient treatment option for IBD patients. The overall business strategy of TLA is aligned to close the remaining clinical and regulatory gap to the market for TLA Gut and commercialise the medical device. The project is the key enabler of this strategy.

Deliverables

List of deliverables.
Project website created and launched	Websites, patent fillings, videos etc.	2019-11-14 10:13:28

Take a look to the deliverables list in detail: detailed list of TLA-Gut deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TLA-GUT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TLA-GUT" are provided by the European Opendata Portal: CORDIS opendata.